Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
John Deanfield, Subodh Verma, Benjamin M. Scirica, et al.
The Lancet (2024) Vol. 404, Iss. 10454, pp. 773-786
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Mikhail Kosiborod, John Deanfield, Richard Pratley, et al.
The Lancet (2024) Vol. 404, Iss. 10456, pp. 949-961
Closed Access | Times Cited: 47
Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 6
From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
Nikolaos Theodorakis, Maria Nikolaou
Biomolecules (2025) Vol. 15, Iss. 2, pp. 213-213
Open Access | Times Cited: 4
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Ralf Weiskirchen, Amedeo Lonardo
British Journal of Pharmacology (2025)
Open Access | Times Cited: 3
Efficacy of GLP-1 Receptor Agonists in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
Shoaib Waqas, Muhammad Umer Sohail, Muhammad Saad, et al.
Journal of Cardiac Failure (2025)
Open Access | Times Cited: 1
Cardiovascular–Endocrine–Metabolic Medicine: Proposing a New Clinical Sub-Specialty Amid the Cardiometabolic Pandemic
Nikolaos Theodorakis, Maria Nikolaou, Andrew J. Krentz
Biomolecules (2025) Vol. 15, Iss. 3, pp. 373-373
Open Access | Times Cited: 1
Thérapeutiques de l’obésité et maladies cardiovasculaires
Pierre Bel Lassen, Judith Aron‐Wisnewsky
Archives des Maladies du Coeur et des Vaisseaux - Pratique (2025)
Closed Access
Obésité et insuffisance cardiaque
Richard Isnard, L. Legrand, Françoise Pousset
Archives des Maladies du Coeur et des Vaisseaux - Pratique (2025)
Closed Access
AMPK-Mediated Multi-Organ Protective Effects of GLP-1 Receptor Agonists
Xin Wang, Linxi Wang
(2025), pp. 4-4
Closed Access
Tratamiento actual de la obesidad: una historia sobre creencias, apegos y confrontación
José M. Balibrea, María Recarte-Rico, María Dolores Frutos
Cirugía Española (2025)
Closed Access
Antiobesity Medications in Patients With Heart Failure
Sureya F Hussani, Kelly Nguyen, Ka Man Yu, et al.
JACC Heart Failure (2025)
Closed Access
Clinical Outcomes of Catheter Ablation for Atrial Fibrillation in Patients with Acute Decompensated Heart Failure
Yoshifumi Ikeda, Ritsushi Kato, Hitoshi Mori, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 629-629
Open Access
Balancing fat loss and muscle loss in the quest to reduce obesity in patients with heart failure
Sheldon E. Litwin
Journal of Cardiac Failure (2025)
Closed Access
Effects of semaglutide on heart failure outcomes
João Sérgio Neves, Milton Packer, João Pedro Ferreira
The Lancet (2025) Vol. 405, Iss. 10478, pp. 542-543
Closed Access
Effects of semaglutide on heart failure outcomes
Jiashu Han, Dan Shan
The Lancet (2025) Vol. 405, Iss. 10478, pp. 542-542
Closed Access
Effects of semaglutide on heart failure outcomes – Author's reply
John Deanfield
The Lancet (2025) Vol. 405, Iss. 10478, pp. 543-544
Closed Access
Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction
Kristian Hellenkamp, Ryosuke Sato, Stephan von Haehling
Med (2025) Vol. 6, Iss. 2, pp. 100570-100570
Closed Access
Glucagon-like peptide–1 receptor agonist for patients with heart failure with preserved ejection fraction and obesity
Linghua Fu, Yao Du, Pingping Yang, et al.
European Journal of Internal Medicine (2025)
Closed Access
Advances in the management of obesity and heart failure: latest evidence from clinical trials
Thomaz Alexandre Costa, Josephine Harrington
Current Opinion in Cardiology (2025)
Closed Access
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
Sten Madsbad, Jens J. Holst
Expert Opinion on Investigational Drugs (2025), pp. 1-19
Open Access
Deep Learning-Enhanced Light Sheet Microscopy Unveils Semaglutide Impact on Cardiac Fibrosis
Sheyla Barrado-Ballestero, Sarah Torp Yttergren, Max Hahn, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies
S. Thompson, Ashwin Roy, Tarekegn Geberhiwot, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 624-624
Open Access
Leptin and heart failure: the chicken or the egg?
Nikolaos Theodorakis, Maria Nikolaou
Heart Failure Reviews (2025)
Closed Access
The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management
Blair Suter, Allison Rhodes, Allison Bigeh, et al.
Current Cardiovascular Risk Reports (2025) Vol. 19, Iss. 1
Open Access
Cardioprotective effects of semaglutide on isolated human ventricular myocardium
Thomas Krammer, Maria J. Baier, Philipp Hegner, et al.
European Journal of Heart Failure (2025)
Open Access
Page 1 - Next Page

Scroll to top